Oxazepam (Alepam 15)
Oxazepam risk profile, scheduling, and guidance for claims professionals and care workers . Also known as Alepam 15, Serepax, OXAZEPAM-WGR, APO-Oxazepam, Murelax and 1 more.
Oxazepam (brand names: Alepam 15, Serepax, OXAZEPAM-WGR, APO-Oxazepam, Murelax and 1 more) is classified as Moderate risk (3 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. Benzodiazepine with significant sedation, impaired coordination and respiratory depression risk.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Moderate (3 points)
- CNS depressant: May cause sedation, impair driving, and affect work capacity
- Respiratory depression risk: Requires monitoring, especially with other CNS depressants
- Recommended maximum duration: 30 days
- SIRA reportable: Flagged for NSW workers compensation reporting
- PBS listed: Subsidised under the Australian Pharmaceutical Benefits Scheme
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | PBS listed |
Risk Profile
Benzodiazepine with significant sedation, impaired coordination and respiratory depression risk.
Regulatory and Compliance Guidance
When Oxazepam appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.
Work capacity impact: As a CNS depressant, Oxazepam may impair driving, operating machinery, and cognitive function. Work capacity certificates should reflect any medication-related restrictions.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
Listed on the Pharmaceutical Benefits Scheme (PBS) for subsidised prescribing.
Flagged as reportable under SIRA guidelines in NSW. Claims involving this medication may require additional reporting and clinical justification.
All Australian workers compensation schemes flag benzodiazepine use as high-risk, particularly when combined with opioids. Duration should be limited and tapering plans documented.
United States FDA / CDC / State WC
The CDC and FDA have issued joint warnings about the risks of concurrent benzodiazepine and opioid use. Workers compensation adjusters should flag this combination for clinical review.
Check this medication against your full medication list
Run a full risk assessment including Oxazepam interactions and compliance checks.
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.